Ecolab Schedules Webcast and Conference Call on February 11th

ST. PAUL, Minn.–(BUSINESS WIRE)–Ecolab will host a live webcast to discuss its 2024 fourth quarter results. A news release containing fourth quarter results is expected to be issued before market open on February 11, 2025. Details for the public webcast are as follows: TIME: 1:00 p.m. Eastern Time DATE: Tuesday, February 11, 2025 DURATION: One hour LOCATION: www.ecolab.com/investor ARCHIVE: A replay of the webcast and supplemental data will be available on Ecolab’s website. About Ecolab A tru
Read More

Stevanato Group to Present at Upcoming Investor Conference

PIOMBINO DESE, Italy–(BUSINESS WIRE)–Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET. A live event webcast will be available on the Company’s website at www.stevanatogroup.com under the “Investors” sec
Read More

Healthpeak Properties Announces Fourth Quarter 2024 Earnings Release Date and Conference Call Details

DENVER–(BUSINESS WIRE)–Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report fourth quarter and full year 2024 financial results after the close of trading on the New York Stock Exchange on Monday, February 3, 2025. Healthpeak will host a conference call and webcast on Tuesday, February 4, 2025, at 8:00 a.m. Mountain Time (10:00 a.m. Eastern Time) to review its financial performance and op
Read More

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenu
Read More

Bruker Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.–(BUSINESS WIRE)—- $BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 13th, 2025 at 3:45 PM Pacific Standard Time. A live audio webcast of the presentation will
Read More

QIAGEN liefert genomische Inhalte für britische Initiative zur Genomsequenzierung von 100.000 Neugeborenen

Redwood City, Kalifornien, und Venlo, Niederlande–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine Partnerschaft mit Genomics England bekannt gegeben, um die Durchführung der Generation Study zu unterstützen. Ziel dieser einzigartigen Initiative ist es, die Genome von 100.000 Neugeborenen in England zu sequenzieren. Damit sollen über 200 ausgewählte Erkrankungen frühzeitig erkannt und seltene Krankheiten schneller behandelt werden. Mithilfe seiner Clinical Kno
Read More

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

REDWOOD CITY, Calif. & VENLO, The Netherlands–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study. This first-of-its-kind initiative aims to sequence the genomes of 100,000 newborns in England to screen for over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions. Through its Clinical Knowledge Base, QIAGEN will be the only company to prov
Read More

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance. Preliminary Full Year 2024 Revenue Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 million for the full year of 2023, an increase of 15%, and above the company’s previous full year guidance range of $83.0
Read More
Top